Research programme: TCR-gene-transduced autologous lymphocytes - Takara Bio

Drug Profile

Research programme: TCR-gene-transduced autologous lymphocytes - Takara Bio

Alternative Names: RetroNectin® gene therapy - Takara Bio; RetroNectin® TCR gene therapy - Takara Bio; TCR gene therapy - Takara Bio; TCR gene transduced autologous lymphocytes - Takara Bio

Latest Information Update: 11 Apr 2014

Price : $50

At a glance

  • Originator Takara Bio
  • Developer Mie University; National Cancer Institute (USA); Takara Bio
  • Class Cell therapies; Gene therapies
  • Mechanism of Action Gene transference; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 11 Apr 2014 TCR-gene-transduced autologous lymphocytes are still in preclinical studies for Cancer in Japan
  • 01 Dec 2011 TCR-gene-transduced autologous lymphocytes are still in preclinical studies for Cancer in Japan
  • 08 Dec 2009 Pharmacodynamics data from a preclinical trial in Cancer presented at the 51st Annual Meeting and Exposition of the American Society of Hematology (ASH-2009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top